DTPACE

DTPACE is a combination chemotherapy regimen used primarily for the treatment of multiple myeloma, especially in patients who are relapsed or refractory to prior therapies. The regimen consists of six drugs: - dexamethasone (a corticosteroid with anti-inflammatory and cytotoxic effects) - thalidomide (an immunomodulatory agent that modifies immune response and has anti-angiogenic properties) - cisplatin (a platinum-based alkylating agent that causes DNA crosslinking and apoptosis) - doxorubicin (an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II) - cyclophosphamide (an alkylating agent causing DNA damage) - etoposide (a topoisomerase II inhibitor leading to DNA strand breaks) DTPACE is typically administered as an intensive salvage therapy or induction therapy before autologous stem cell transplantation. It targets cancer cells through multiple mechanisms including direct cytotoxicity, immunomodulation, inhibition of angiogenesis, and interference with cell division[1][2][3][5][6].

Other names

DT-PACEdexamethasone + thalidomide + cisplatin + doxorubicin + cyclophosphamide + etoposide